Autopsy report · NCT06690281

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

“PI left NIH.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Gastrointestinal Carcinoma; Pancreatic Cancer; Hepatocellular Cancer; Cholangiocarcinoma; Duodenal Cancer; Colorectal Cancer

Interventions

KRAS TCR-Transduced PBL; Aldesleukin; Fludarabine; Cyclophosphamide

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)
  “PI leaving NIH.” (93% match in meaning)
• Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure
  “Departure of PI” (80% match in meaning)
• Immersive VR Environments to Induce and Evaluate Cognitive Fatigability
  “PI left the NIH. Study will not continue.” (77% match in meaning)
• Brain Autoregulation Research Study
  “PI departure” (74% match in meaning)
• Adjunct Dexmedetomidine (Precedex®) Therapy Impact on Sedative and Analgesic Requirement
  “PI resigned.” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.